SAN DIEGO, May 12, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended March 31, 2016 and provided an update on its corporate activities and product pipeline. First Quarter 2016 and Subsequent Highlights Phase 2 Candidemia Clinical Trial On Track: Cidara conducted an End-of-Phase 1 meeting with the FDA and has begun clinical site initiation…

Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies of its novel echinocandin, CD101, will be presented at the 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam,…

SAN DIEGO, April 05, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Needham & Company 15th Annual Healthcare Conference on Tuesday, April 12, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 3:00 p.m. EDT (12:00 p.m. PDT). The conference is being held in New York City. A…

SAN DIEGO, March 18, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months and full year ended December 31, 2015 and provided an update on its corporate activities and product pipeline. Fourth Quarter 2015 and Subsequent Highlights Announced Positive Data from Single and Multiple Dose Phase 1 Clinical Trials of CD101 IV; on track to initiate…

Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Headline of release should read: Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (instead of Cidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis) The corrected release reads: CIDARA RECEIVES ORPHAN DRUG DESIGNATION FOR NOVEL ECHINOCANDIN, CD101 IV, IN CANDIDEMIA AND INVASIVE CANDIDIASIS Orphan designation follows QIDP and…

Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis. Orphan drug designation of CD101 provides Cidara eligibility for seven years of market…

SAN DIEGO, Feb. 03, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to conduct a fireside chat from 2:40 p.m.- 3:00 p.m. EST. The conference is being held at the Waldorf…

-- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability - SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced data from the company's Phase 1 multiple ascending dose clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 IV is a novel, long-acting echinocandin that Cidara is developing for the treatment and prevention of serious, invasive fungal…

New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, commends the Infectious Diseases Society of America (IDSA) for new clinical guidelines that recognize the important role of echinocandins in the initial treatment of invasive fungal infections. Specifically, the guidelines recommend a shift from fluconazole to echinocandins as first-line treatment for invasive candidiasis and…

Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced positive data from the company's Phase 1 single ascending dose (SAD) clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 IV is a novel,…